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potential way forward for a dual imaging approach in this youn-
ger age group.
doi:10.1016/j.ejcsup.2010.06.084
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Objective: The purpose of the current study was to compare the
diagnostic accuracy of two-view full-field digital mammography
(FFDM) with co-registered two-view digital breast tomosynthesis
(DBT).
Methods: The ethics committee approved trial evaluating a
Hologic Selenia Dimensions machine recruited women recalled
after their initial breast screening using analogue film-screen
mammography, scheduled to undergo further breast assessment
following informed consent. Radiologists fulfilling the profes-
sional criteria for National Health Service Breast Screening Pro-
gramme’s radiology practice reviewed all images using the Royal
College of Radiologists Breast Group classification for mammo-
graphic features 1–5 (M1 = normal, M2 = benign, M3 = probably
benign, M4 = suspicious, M5 = malignant).
Results: The study included bilateral mammograms of 526
women (age range 47–73 years) with 119 (22.6%) histologically
proven primary breast cancers assessed by 5 readers.
Using receiver operating characteristic (ROC) test, the analysis
yielded statistically significant difference (p = 0.0001) between
FFDM and DBT. The area under the ROC curve (AUC) was
0.968 ± 0.007 for DBT compared to AUC of 0.913 ± 0.015 for FFDM,
demonstrating DBT interpretation was superior.
Conclusion: Patients recalled after routine screening mammog-
raphy will benefit from DBT as an additional technique for diag-
nostic workup.
doi:10.1016/j.ejcsup.2010.06.085
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Background: NICE guidelines advocate use of AIs within licence
for all but low risk patients. Early discharge at three years is also
recommended. To gauge interest in extended adjuvant endocrine
therapy research treatment practice and follow up practice needs
to be understood.
Methods: A survey designed to capture current practice for ER
positive, post-menopausal women who have completed 5 years
of treatment with an AI was distributed to 774 oncologists and
surgeons from 285 centres across the UK. The survey also cap-
tured opinion on a proposed trial of further treatment in this
patient group.
Results: A total of 159 clinicians (65 clinical oncologists; 28
medical oncologists; 63 surgeons and 3 others) responded to the
survey, representing 102 hospitals. The most common time for
routine discharge was 5 years regardless of nodal involvement
58% vs 12% before and 23% after 5 years. Patients with more than
4 nodes positive were discharged later than 5 years by 36%
respondents. The majority of respondents discontinue AIs at 5
years for node negative but continue AI use beyond 5 years in
node positive cases.
92% of responders expressed interest in participating in a clin-
ical trial of extended endocrine therapy most frequently selecting
node positive cases as the target population.
Conclusions: There is substantial variation in follow-up practice
and treatment for ER positive, post-menopausal women following
5 years of AI containing endocrine therapy within the UK. Many
clinicians would support a clinical trial of extended hormone
therapy in node positive patients.
doi:10.1016/j.ejcsup.2010.06.086
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Introduction: The number of women with stage IV disease who
have primary or delayed breast reconstruction is small. The pri-
mary aim of this study was to establish current UK practice and
opinions with regards to the appropriateness of breast recon-
struction in stage IV disease.
Methods: All 485 full members of the Association of Breast Sur-
geons (ABS) and all 378 full members of the British Association of
Plastic Reconstructive and Aesthetic Surgeons (BAPRAS) were
invited by email to take part in an online survey.
Results: Of the breast surgeons, 101 responded (26.9%). Of the
plastic surgeons 59 responded (16%). 78.9% would operate on
the primary tumour, mainly for local control. Plastic surgeons
showed a propensity for immediate reconstruction compared to
their breast surgery colleagues, and 26.6% of breast surgeons
would not offer reconstruction at all. Immediate latissimus dorsi
(LD) flap and implant was the favoured method in early stage dis-
ease (100%), with delayed LD and implant the most popular
option for stage IV disease (77.0%).
In patients who have already had a mastectomy, the majority
(54.4%) would offer reconstruction if stability of disease progres-
sion has been demonstrated.
32 EJC SUPPLEMENTS 8 (2010) 1–36
